Overview
ZNTL market data
Price History
ZNTL price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$1.91 Diluted earnings per share over the trailing twelve months.
- Beta
- 1.91 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- — Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $1.21 – $6.95 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · source Twelve Data /statistics · market cap $357.2 · P/B 0.45.
Company News
Rodman & Renshaw Initiates Coverage On Zentalis Pharmaceuticals with Buy Rating, Announces Price Target of $11Benzinga · Jul 23, 2026, 7:14 PM
Zentalis Pharmaceuticals shares are trading higher after Mizuho initiated its coverage on the stock with an Outperform rating and announced a price target of $8.Benzinga · Jul 17, 2026, 2:26 PM
ManpowerGroup Posts Upbeat Q2 Earnings, Joins Docebo, Zentalis Pharmaceuticals And Other Big Stocks Moving Higher On FridayBenzinga · Jul 17, 2026, 2:09 PM
Mizuho Initiates Coverage On Zentalis Pharmaceuticals with Outperform Rating, Announces Price Target of $8Benzinga · Jul 17, 2026, 11:23 AM
Osteosarcoma Therapeutics Pipeline 2026: Explore 25+ Companies and 32+ Pipeline DrugsGlobenewswire Inc · Jul 3, 2026, 2:15 PM
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Globenewswire Inc · Jun 1, 2026, 9:30 PM
8-K filing — Zentalis Pharmaceuticals, Inc. (ZNTL)SEC EDGAR · May 27, 2026, 8:07 PM
Zentalis Pharmaceuticals Azenosertib Plus Paclitaxel Shows 50% Response Rate And 9.2-Month Duration Of Response In Phase 1b Platinum-Resistant Ovarian Cancer Study With Manageable Safety ProfileBenzinga · May 21, 2026, 9:55 PM
Zentalis Pharmaceuticals To Reveal Its Phase 1b MUIR Trial Data Showing Clinical Activity And Manageable Safety Profile of Azenosertib Plus Paclitaxel In Platinum-Resistant Ovarian Cancer At ASCO 2026; Activity Of The Combined Regimen Across All Dose Cohorts Achieved 39% ORR And 7.3-Month Median PFS;Benzinga · May 21, 2026, 9:50 PM
Zentalis Pharma Q1 EPS $(0.50) Misses $(0.47) EstimateBenzinga · May 12, 2026, 9:20 PM